Key Highlights

  • BioPharma Credit PLC (LSE:BPCP) is listed on the London Stock Exchange Main Market with a Dividend Yield of 7.23%.
  • The company targets a 7 US cent base annual dividend, paid quarterly at 1.75 cents.
  • Total dividends for 2025 were 9.95 cents, including a 1.446 cent special in Q4.
  • Quarterly dividends of 1.75 cents were declared for Q2 and Q3 2026.
  • Total dividends since IPO in 2017 reached 76.88 cents.
  • New loans include up to $125m committed to Zenas BioPharma and $50m to Paratek.

Overview of BioPharma Credit

BioPharma Credit PLC (LSE:BPCP, also quoted as BPCR) is a specialist life sciences Debt investor managed by Pharmakon Advisors. It lends to pharmaceutical and biotech companies, typically secured on approved products and royalties. Loans usually pay floating-rate interest plus fees.

The 7.23% yield reflects the 7 cent base dividend plus special distributions.

Dividend Policy

BPCP targets a 7 cent base dividend in four quarterly payments of 1.75 cents, supplemented by special dividends from excess income, typically in Q4 and sometimes Q3, to meet Investment trust distribution rules. The Q4 2025 dividend was 3.196 cents, comprising 1.75 cents ordinary and 1.446 cents special, bringing 2025 dividends to 9.95 cents. Dividends were 10.18 cents for 2024 and 10.21 cents for 2023.

In 2026, BPCP declared 1.75 cents for Q2, paid on 31 July 2026, and 1.75 cents for Q3, payable on 6 November 2026. It has paid at least 1.75 cents every quarter since June 2018.

Dividend Cover

Interest income from loans comfortably covers the base dividend, with excess income paid as specials. Data providers show trailing payout ratios around 85%.

Portfolio and Cash Flows

BPCP's loans earn high interest rates, often floating, plus prepayment fees when borrowers repay early. Repayments can generate one-off income, boosting specials. New commitments, such as Zenas BioPharma and Paratek, redeploy capital.

Discount Control

Shares traded at about a 10% discount to NAV at the end of 2025. BPCP has bought back shares, holding about 244.7 million in treasury, which supports NAV per share.

Currency

Dividends are paid in US dollars by default, with a sterling election available.

Why Life Sciences Lending Works

Life sciences companies with approved drugs often generate strong revenues but prefer debt to diluting shareholders with new equity. BioPharma Credit fills this gap with senior secured loans, often protected by the value of intellectual property and product cash flows. These loans tend to carry higher interest rates than conventional corporate debt, reflecting the specialised nature of the sector. Because healthcare spending is relatively insensitive to economic cycles, borrower revenues can be more stable than those in cyclical industries, supporting income through downturns.

Floating Rate Benefit

Many loans pay interest linked to short-term rates, so BPCP's income rose as rates increased. Falling rates would reduce income, but the 7 cent base dividend has been set conservatively to allow for this.

Prepayment Income

When borrowers refinance early, BPCP often receives prepayment fees, which boost income in that year. These one-off gains have historically funded special dividends. The flip side is that the Capital must then be redeployed into new loans, which can take time.

Recent Deployments

The commitment of up to $125m to Zenas BioPharma and $50m of financing for Paratek show the manager continues to find opportunities to put capital to work at attractive terms.

Risks

Risks include borrower defaults, early repayments reducing future income, lower interest rates and concentration in a limited number of loans.

Market Sentiment

The dividend yield on NAV was around 10.9% at the end of 2025, highlighting the income on offer. Commentary describes BPCP as a reliable income vehicle with a strong record. Shares traded around 95 cents in mid-2026.

How BPCP Fits an Income Portfolio

BPCP offers uncorrelated income from healthcare lending, diversifying traditional credit exposure.

Manager Expertise

Pharmakon has decades of experience in life sciences credit, carefully structuring loans backed by commercial products.

Dividend Sustainability Scorecard

  • Base dividend: 7 cents a year.
  • Specials: paid from excess income.
  • Track record: at least 1.75 cents every quarter since 2018.
  • Discount: managed through buybacks.
  • Key risk: borrower defaults and lower rates.

What Investors Should Watch

Watch the Q4 2026 dividend and any special, new Loan deployments, repayments and Interest Rate trends.

Is the 7.23% Yield Sustainable?

BPCP's 7 cent base dividend looks highly sustainable, with specials as upside. LSE:BPCP suits investors seeking steady dollar income from specialist credit.